Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:52 UTC |
---|
Update Date | 2022-03-07 02:51:58 UTC |
---|
HMDB ID | HMDB0015397 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Sunitinib |
---|
Description | Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. |
---|
Structure | CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12- |
---|
Synonyms | Value | Source |
---|
SU-11248 | ChEBI | Sunitinibum | ChEBI | Sutent | ChEBI | SU11248 | HMDB | Sunitinib malate | HMDB | 5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide | HMDB |
|
---|
Chemical Formula | C22H27FN4O2 |
---|
Average Molecular Weight | 398.4738 |
---|
Monoisotopic Molecular Weight | 398.211804333 |
---|
IUPAC Name | N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide |
---|
Traditional Name | sunitinib |
---|
CAS Registry Number | 557795-19-4 |
---|
SMILES | CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C |
---|
InChI Identifier | InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12- |
---|
InChI Key | WINHZLLDWRZWRT-ATVHPVEESA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as indolines. Indolines are compounds containing an indole moiety, which consists of pyrrolidine ring fused to benzene to form 2,3-dihydroindole. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Indoles and derivatives |
---|
Sub Class | Indolines |
---|
Direct Parent | Indolines |
---|
Alternative Parents | |
---|
Substituents | - Dihydroindole
- Pyrrole-3-carboxamide
- Pyrrole-3-carboxylic acid or derivatives
- Aryl fluoride
- Aryl halide
- Substituted pyrrole
- Benzenoid
- Pyrrole
- Heteroaromatic compound
- Vinylogous amide
- Tertiary amine
- Amino acid or derivatives
- Secondary carboxylic acid amide
- Tertiary aliphatic amine
- Carboxamide group
- Lactam
- Azacycle
- Carboxylic acid derivative
- Amine
- Organofluoride
- Organohalogen compound
- Organonitrogen compound
- Organopnictogen compound
- Organooxygen compound
- Organic oxide
- Carbonyl group
- Organic oxygen compound
- Organic nitrogen compound
- Hydrocarbon derivative
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.031 g/L | Not Available | LogP | 2.5 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times UnderivatizedChromatographic Method | Retention Time | Reference |
---|
Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.24 minutes | 32390414 | Predicted by Siyang on May 30, 2022 | 10.256 minutes | 33406817 | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.58 minutes | 32390414 | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 118.7 seconds | 40023050 | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1043.3 seconds | 40023050 | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 174.4 seconds | 40023050 | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 157.7 seconds | 40023050 | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 161.8 seconds | 40023050 | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 67.6 seconds | 40023050 | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 306.6 seconds | 40023050 | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 398.4 seconds | 40023050 | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 421.5 seconds | 40023050 | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 733.4 seconds | 40023050 | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 292.4 seconds | 40023050 | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1007.7 seconds | 40023050 | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 221.2 seconds | 40023050 | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 287.2 seconds | 40023050 | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 315.0 seconds | 40023050 | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 393.4 seconds | 40023050 | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 69.3 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Sunitinib,1TMS,isomer #1 | CCN(CC)CCN(C(=O)C1=C(C)[NH]C(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C)[Si](C)(C)C | 3452.8 | Semi standard non polar | 33892256 | Sunitinib,1TMS,isomer #1 | CCN(CC)CCN(C(=O)C1=C(C)[NH]C(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C)[Si](C)(C)C | 3335.7 | Standard non polar | 33892256 | Sunitinib,1TMS,isomer #1 | CCN(CC)CCN(C(=O)C1=C(C)[NH]C(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C)[Si](C)(C)C | 4546.5 | Standard polar | 33892256 | Sunitinib,1TMS,isomer #2 | CCN(CC)CCNC(=O)C1=C(C)N([Si](C)(C)C)C(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C | 3544.6 | Semi standard non polar | 33892256 | Sunitinib,1TMS,isomer #2 | CCN(CC)CCNC(=O)C1=C(C)N([Si](C)(C)C)C(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C | 3429.0 | Standard non polar | 33892256 | Sunitinib,1TMS,isomer #2 | CCN(CC)CCNC(=O)C1=C(C)N([Si](C)(C)C)C(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C | 4484.6 | Standard polar | 33892256 | Sunitinib,1TMS,isomer #3 | CCN(CC)CCNC(=O)C1=C(C)[NH]C(/C=C2\C(=O)N([Si](C)(C)C)C3=CC=C(F)C=C23)=C1C | 3447.4 | Semi standard non polar | 33892256 | Sunitinib,1TMS,isomer #3 | CCN(CC)CCNC(=O)C1=C(C)[NH]C(/C=C2\C(=O)N([Si](C)(C)C)C3=CC=C(F)C=C23)=C1C | 3083.4 | Standard non polar | 33892256 | Sunitinib,1TMS,isomer #3 | CCN(CC)CCNC(=O)C1=C(C)[NH]C(/C=C2\C(=O)N([Si](C)(C)C)C3=CC=C(F)C=C23)=C1C | 4051.5 | Standard polar | 33892256 | Sunitinib,2TMS,isomer #1 | CCN(CC)CCN(C(=O)C1=C(C)N([Si](C)(C)C)C(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C)[Si](C)(C)C | 3438.2 | Semi standard non polar | 33892256 | Sunitinib,2TMS,isomer #1 | CCN(CC)CCN(C(=O)C1=C(C)N([Si](C)(C)C)C(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C)[Si](C)(C)C | 3457.2 | Standard non polar | 33892256 | Sunitinib,2TMS,isomer #1 | CCN(CC)CCN(C(=O)C1=C(C)N([Si](C)(C)C)C(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C)[Si](C)(C)C | 4261.0 | Standard polar | 33892256 | Sunitinib,2TMS,isomer #2 | CCN(CC)CCN(C(=O)C1=C(C)[NH]C(/C=C2\C(=O)N([Si](C)(C)C)C3=CC=C(F)C=C23)=C1C)[Si](C)(C)C | 3323.0 | Semi standard non polar | 33892256 | Sunitinib,2TMS,isomer #2 | CCN(CC)CCN(C(=O)C1=C(C)[NH]C(/C=C2\C(=O)N([Si](C)(C)C)C3=CC=C(F)C=C23)=C1C)[Si](C)(C)C | 3166.5 | Standard non polar | 33892256 | Sunitinib,2TMS,isomer #2 | CCN(CC)CCN(C(=O)C1=C(C)[NH]C(/C=C2\C(=O)N([Si](C)(C)C)C3=CC=C(F)C=C23)=C1C)[Si](C)(C)C | 3820.4 | Standard polar | 33892256 | Sunitinib,2TMS,isomer #3 | CCN(CC)CCNC(=O)C1=C(C)N([Si](C)(C)C)C(/C=C2\C(=O)N([Si](C)(C)C)C3=CC=C(F)C=C23)=C1C | 3448.6 | Semi standard non polar | 33892256 | Sunitinib,2TMS,isomer #3 | CCN(CC)CCNC(=O)C1=C(C)N([Si](C)(C)C)C(/C=C2\C(=O)N([Si](C)(C)C)C3=CC=C(F)C=C23)=C1C | 3240.2 | Standard non polar | 33892256 | Sunitinib,2TMS,isomer #3 | CCN(CC)CCNC(=O)C1=C(C)N([Si](C)(C)C)C(/C=C2\C(=O)N([Si](C)(C)C)C3=CC=C(F)C=C23)=C1C | 3777.5 | Standard polar | 33892256 | Sunitinib,3TMS,isomer #1 | CCN(CC)CCN(C(=O)C1=C(C)N([Si](C)(C)C)C(/C=C2\C(=O)N([Si](C)(C)C)C3=CC=C(F)C=C23)=C1C)[Si](C)(C)C | 3378.1 | Semi standard non polar | 33892256 | Sunitinib,3TMS,isomer #1 | CCN(CC)CCN(C(=O)C1=C(C)N([Si](C)(C)C)C(/C=C2\C(=O)N([Si](C)(C)C)C3=CC=C(F)C=C23)=C1C)[Si](C)(C)C | 3306.8 | Standard non polar | 33892256 | Sunitinib,3TMS,isomer #1 | CCN(CC)CCN(C(=O)C1=C(C)N([Si](C)(C)C)C(/C=C2\C(=O)N([Si](C)(C)C)C3=CC=C(F)C=C23)=C1C)[Si](C)(C)C | 3587.9 | Standard polar | 33892256 | Sunitinib,1TBDMS,isomer #1 | CCN(CC)CCN(C(=O)C1=C(C)[NH]C(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C)[Si](C)(C)C(C)(C)C | 3666.9 | Semi standard non polar | 33892256 | Sunitinib,1TBDMS,isomer #1 | CCN(CC)CCN(C(=O)C1=C(C)[NH]C(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C)[Si](C)(C)C(C)(C)C | 3519.3 | Standard non polar | 33892256 | Sunitinib,1TBDMS,isomer #1 | CCN(CC)CCN(C(=O)C1=C(C)[NH]C(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C)[Si](C)(C)C(C)(C)C | 4552.0 | Standard polar | 33892256 | Sunitinib,1TBDMS,isomer #2 | CCN(CC)CCNC(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C | 3710.1 | Semi standard non polar | 33892256 | Sunitinib,1TBDMS,isomer #2 | CCN(CC)CCNC(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C | 3629.0 | Standard non polar | 33892256 | Sunitinib,1TBDMS,isomer #2 | CCN(CC)CCNC(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C | 4483.1 | Standard polar | 33892256 | Sunitinib,1TBDMS,isomer #3 | CCN(CC)CCNC(=O)C1=C(C)[NH]C(/C=C2\C(=O)N([Si](C)(C)C(C)(C)C)C3=CC=C(F)C=C23)=C1C | 3654.3 | Semi standard non polar | 33892256 | Sunitinib,1TBDMS,isomer #3 | CCN(CC)CCNC(=O)C1=C(C)[NH]C(/C=C2\C(=O)N([Si](C)(C)C(C)(C)C)C3=CC=C(F)C=C23)=C1C | 3298.9 | Standard non polar | 33892256 | Sunitinib,1TBDMS,isomer #3 | CCN(CC)CCNC(=O)C1=C(C)[NH]C(/C=C2\C(=O)N([Si](C)(C)C(C)(C)C)C3=CC=C(F)C=C23)=C1C | 4064.5 | Standard polar | 33892256 | Sunitinib,2TBDMS,isomer #1 | CCN(CC)CCN(C(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C)[Si](C)(C)C(C)(C)C | 3787.9 | Semi standard non polar | 33892256 | Sunitinib,2TBDMS,isomer #1 | CCN(CC)CCN(C(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C)[Si](C)(C)C(C)(C)C | 3818.4 | Standard non polar | 33892256 | Sunitinib,2TBDMS,isomer #1 | CCN(CC)CCN(C(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C)[Si](C)(C)C(C)(C)C | 4325.8 | Standard polar | 33892256 | Sunitinib,2TBDMS,isomer #2 | CCN(CC)CCN(C(=O)C1=C(C)[NH]C(/C=C2\C(=O)N([Si](C)(C)C(C)(C)C)C3=CC=C(F)C=C23)=C1C)[Si](C)(C)C(C)(C)C | 3713.6 | Semi standard non polar | 33892256 | Sunitinib,2TBDMS,isomer #2 | CCN(CC)CCN(C(=O)C1=C(C)[NH]C(/C=C2\C(=O)N([Si](C)(C)C(C)(C)C)C3=CC=C(F)C=C23)=C1C)[Si](C)(C)C(C)(C)C | 3553.0 | Standard non polar | 33892256 | Sunitinib,2TBDMS,isomer #2 | CCN(CC)CCN(C(=O)C1=C(C)[NH]C(/C=C2\C(=O)N([Si](C)(C)C(C)(C)C)C3=CC=C(F)C=C23)=C1C)[Si](C)(C)C(C)(C)C | 3918.9 | Standard polar | 33892256 | Sunitinib,2TBDMS,isomer #3 | CCN(CC)CCNC(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(/C=C2\C(=O)N([Si](C)(C)C(C)(C)C)C3=CC=C(F)C=C23)=C1C | 3819.6 | Semi standard non polar | 33892256 | Sunitinib,2TBDMS,isomer #3 | CCN(CC)CCNC(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(/C=C2\C(=O)N([Si](C)(C)C(C)(C)C)C3=CC=C(F)C=C23)=C1C | 3624.3 | Standard non polar | 33892256 | Sunitinib,2TBDMS,isomer #3 | CCN(CC)CCNC(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(/C=C2\C(=O)N([Si](C)(C)C(C)(C)C)C3=CC=C(F)C=C23)=C1C | 3866.0 | Standard polar | 33892256 | Sunitinib,3TBDMS,isomer #1 | CCN(CC)CCN(C(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(/C=C2\C(=O)N([Si](C)(C)C(C)(C)C)C3=CC=C(F)C=C23)=C1C)[Si](C)(C)C(C)(C)C | 3903.1 | Semi standard non polar | 33892256 | Sunitinib,3TBDMS,isomer #1 | CCN(CC)CCN(C(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(/C=C2\C(=O)N([Si](C)(C)C(C)(C)C)C3=CC=C(F)C=C23)=C1C)[Si](C)(C)C(C)(C)C | 3840.7 | Standard non polar | 33892256 | Sunitinib,3TBDMS,isomer #1 | CCN(CC)CCN(C(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(/C=C2\C(=O)N([Si](C)(C)C(C)(C)C)C3=CC=C(F)C=C23)=C1C)[Si](C)(C)C(C)(C)C | 3779.6 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Sunitinib GC-MS (Non-derivatized) - 70eV, Positive | splash10-001r-9043000000-f9288d8cb7c447b10d86 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Sunitinib GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Sunitinib GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sunitinib 10V, Positive-QTOF | splash10-0002-0419000000-d91569989d4c1e438a58 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sunitinib 20V, Positive-QTOF | splash10-1039-4964000000-32cdbd9b3679f4b806d9 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sunitinib 40V, Positive-QTOF | splash10-00di-9740000000-14530852543a6132d98b | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sunitinib 10V, Negative-QTOF | splash10-0002-0019000000-716107e6148bcb3af14c | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sunitinib 20V, Negative-QTOF | splash10-052b-5398000000-e20fbe1cd3f11ad37acb | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sunitinib 40V, Negative-QTOF | splash10-0006-9230000000-0d8caf257003c837c3d6 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sunitinib 10V, Positive-QTOF | splash10-0002-0009000000-c7521df282758983a81b | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sunitinib 20V, Positive-QTOF | splash10-003r-0197000000-fc31f5a3f60673e3fb48 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sunitinib 40V, Positive-QTOF | splash10-0a4i-0293000000-c9aae10759016725c932 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sunitinib 10V, Negative-QTOF | splash10-0002-0009000000-f6f1dd2f48935333770c | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sunitinib 20V, Negative-QTOF | splash10-0002-2049000000-fe9e71e910a9eddb2023 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sunitinib 40V, Negative-QTOF | splash10-052g-6194000000-ce0d447fabdb293e1813 | 2021-10-11 | Wishart Lab | View Spectrum |
|
---|
General References | - Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006 Oct 14;368(9544):1329-38. [PubMed:17046465 ]
- Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):115-24. [PubMed:17215529 ]
- (). FDA label . .
|
---|